The landmark launch of Orasure Technologies' OraQuick In-Home HIV test last year was a key driver behind the 5.4% growth in the home-test kit category for the 12 weeks ended Dec. 30 across U.S. multi-outlets, according to SymphonyIRI Group data.
With private label across analgesics up an estimated 11.3% to $1.7 billion, retailers are going to need to make some tough decisions as two internal analgesic powerhouses — McNeil's Tylenol and Novartis' Excedrin — make their way back onto market after respective recalls.
Much of the policy-making conversation about health care in recent years has sought to highlight anticipated cost savings from technology innovation. Critics say this is an outgrowth of the American "fix-it" mentality. Others say technical solutions have yet to take hold outside of medical accounting applications. But there is general agreement that in the area of technologies to nurture medication adherence, the ground remains fertile.
Has the explosion in generic utilization curbed pioneer-drug research and development? That's one concern floated by some pharmaceutical industry watchers, who claim that the stunning market share gains made by generic drug makers could reduce incentives for branded drug companies to spend to develop new molecular entities, conduct lengthy clinical trials, gain FDA approval and bring those new drugs to market.
Canadian generic drug makers expressed dismay over a new plan to reduce reimbursements for a half-dozen generic medications in most of the country's provinces. According to published reports, a group of premiers had reached a coordinated deal to reduce the prices their governments paid for six generic drugs, hoping to save the provinces nearly $100 million.